Posted from: Friday, October 31, 2014 - 12:11 PM - Present

FDA Approves New Indications for Taclonex

September 30, 2014 – The US Food and Drug Administration (FDA) approved Leo Pharma’s Taclonex Topical Suspension (calcipotriene and betamethasone dipropionate) to treat adolescents ages 12-17 who have plaque psoriasis of the scalp.



If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.


Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.


*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Tuesday, October 22, 2019 - 03:10 PM.